Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 


Online Report Subscribers, Click Here
Pricing and Ordering Information

Women's Health: U.S. Markets for Osteoporosis Management Products
Report #A302 - January 2008
129 Pages – 30 Exhibits – 11 Key Company Profiles

In 2007, the United States (U.S.) market for osteoporosis management products totaled approximately $7.6 billion. Sales of these products are expected to increase at a compound annual rate of 6.6%, reaching an estimated $9.3 billion in the year 2010.

This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever U.S. Surgeon General’s report on the nation’s bone health, by the year 2020 one out of two Americans over the age of 50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing osteoporosis.

Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers, bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.

Ordering Information

Title

 Report# Publication
Date		 List Price

Women's Health: U.S. Markets for Osteoporosis Management Products

A302

 January 2008

$4,750
Order Online:
Single User only (Please call for corporate subscription pricing)

Print Only

 PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.    Osteoporosis Incidence and Prevalence

ii.    Osteoporosis Diagnosis and Management

a.   Bone Densitometry

b.   Biochemical Markers

c.    Osteoporosis Treatments

iii.   Market Analysis

a.   Bone Densitometry Systems

b.   Biochemical Markers

c.    Hormone Replacement Therapy and Osteoporosis Drugs

i.    Hormone Replacement Therapy Drugs

ii.    Osteoporosis Drugs

iv.   Methodology

 

Exhibit ES-1:    2007, Osteoporosis-Caused Fracture Incidence, by Site

Exhibit ES-2:    Osteoporosis Management Products, Combined Market Forecast, 2005-2010

Exhibit ES-3:    Total Bone Densitometry Systems, Market Forecast, 2005-2010

Exhibit ES-4:    Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010

Exhibit ES-5:    2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category

Exhibit ES-6:    Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010

Exhibit ES-7:    Osteoporosis Drugs, Market Forecast, 2005-2010

Exhibit ES-8:    Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010

 

1.   OSTEOPOROSIS MANAGEMENT PRODUCTS MARKET

1.1 Overview of Osteoporosis

1.1.1 Incidence, Prevalence, and Cost

1.1.2 Types of Osteoporosis

1.1.3 Risk Factors

1.2 Diagnosis

1.2.1 Bone Densitometry

1.2.1.1 Products, by Application

1.2.1.1.1 Hospital-Based Densitometry Systems

1.2.1.1.2 Office-Based Densitometry Systems

1.2.1.1.3 Software-Based Systems

1.2.1.2 Products and Suppliers

1.2.1.2.1 CooperSurgical/The Cooper Companies

1.2.1.2.2 GE Healthcare/General Electric Company

1.2.1.2.3 Hologic

1.2.1.3 Market Analysis

1.2.1.4 Competitive Analysis

1.2.2 Biochemical Markers

1.2.2.1 Types

1.2.2.2 Applications

1.2.2.3 Products and Suppliers

1.2.2.3.1 Beckman Coulter

1.2.2.3.2 Roche Diagnostics/F. Hoffmann- La Roche/Roche Holding

1.2.2.3.3 Inverness Medical Innovations

1.2.2.3.4 Orion Diagnostica Oy/Orion Group

1.2.2.3.5 Quidel

1.2.2.4 Market Analysis

1.2.2.5 Competitive Analysis

1.3 Treatment

1.3.1 Antiresorptive Drugs

1.3.1.1 Estrogen

1.3.1.2 Selective Estrogen Receptor Modulators

1.3.1.2.1 EVISTA

1.3.1.3 Calcitonins

1.3.1.4 Bisphosphonates

1.3.1.4.1 Actonel

1.3.1.4.2 Boniva

1.3.1.4.3 FOSAMAX

1.3.2 Bone-Forming Drugs

1.3.2.1 Sodium Fluoride

1.3.2.2 Parathyroid Hormone

1.3.2.2.1 FORTÉO

1.3.3 Dual-Acting Drug

1.3.4 Other Treatments

1.3.4.1 Monoclonal Antibodies

1.3.4.2 Cathepsin K Inhibitors

1.3.4.3 Gene Therapy

1.3.4.4 Statin Drugs

1.3.4.5 Selective Androgen Receptor Modulators

1.3.5 Market Analysis

1.3.5.1 Hormone Replacement Therapy Drugs

1.3.5.2 Osteoporosis Drugs

1.3.6 Competitive Analysis

1.3.7 Combined Market Analysis

 

Exhibit 1-1:       2007, Osteoporosis-Caused Fracture   Incidence, by Site

Exhibit 1-2:       Prevalence of Osteoporosis and Low Bone Mass in Men and Women Age 50 and Older, by Ethnicity

Exhibit 1-3:      Types of Osteoporosis

Exhibit 1-4:      Leading Risk Factors for Osteoporosis

Exhibit 1-5:       Comparison of Bone Densitometry and Osteoporosis Biochemical Marker Screenings

Exhibit 1-6:       Imaging Technologies Used to Diagnose Osteoporosis

Exhibit 1-7:       2008, Selected Bone Densitometry Systems

Exhibit 1-8:       Bone Densitometry Hospital Systems, Market Forecast, 2005-2010

Exhibit 1-9:       Bone Densitometry Office Systems, Market Forecast, 2005-2010

Exhibit 1-10:     Total Bone Densitometry Systems, Market Forecast, 2005-2010

Exhibit 1-11:     2007, Bone Densitometry Systems Market, Share by Supplier

Exhibit 1-12:     Comparison of Bone Remodeling Biochemical Markers

Exhibit 1-13:     2008, Selected Bone Remodeling Biochemical Marker Tests

Exhibit 1-14:     Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010

Exhibit 1-15:     2007, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier

Exhibit 1-16:     2008, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis

Exhibit 1-17:     Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010

Exhibit 1-18:     2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category

Exhibit 1-19:     Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010

Exhibit 1-20:     Osteoporosis Drugs, Market Forecast, 2005-2010

Exhibit 1-21:     2007, Hormone Replacement Therapy and Osteoporosis Drugs Market, Share by Supplier

Exhibit 1-22:     Osteoporosis Management Products, Combined Market Forecast, 2005-2010

 

2. COMPANY PROFILES

2.1       The Cooper Companies, Inc.

2.2       General Electric Company

2.3       Hologic, Inc.

2.4       Inverness Medical Innovations, Inc.

2.5       Eli Lilly and Company

2.6       Merck & Company, Inc.

2.7       Novartis AG

2.8       Procter & Gamble Company

2.9       Quidel Corporation

2.10     Roche Holding AG

2.11     Wyeth

APPENDIX:  COMPANY LISTING

 

 

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact sales@medtechinsight.com. From outside the U.S., contact internationalsales@medtechinsight.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home